DE2811695A1 - Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis - Google Patents

Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis

Info

Publication number
DE2811695A1
DE2811695A1 DE19782811695 DE2811695A DE2811695A1 DE 2811695 A1 DE2811695 A1 DE 2811695A1 DE 19782811695 DE19782811695 DE 19782811695 DE 2811695 A DE2811695 A DE 2811695A DE 2811695 A1 DE2811695 A1 DE 2811695A1
Authority
DE
Germany
Prior art keywords
psoriasis
pig brain
medicaments
adenosine phosphate
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19782811695
Other languages
German (de)
Inventor
Nichtnennung Beantragt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brauegg Arzneimittel KG Bernd Sotek 7570 Baden-Ba
Original Assignee
BRAUEGG ARZNEIMITTEL KG BERND
BRAUEGG ARZNEIMITTEL KG BERND SOTEK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAUEGG ARZNEIMITTEL KG BERND, BRAUEGG ARZNEIMITTEL KG BERND SOTEK filed Critical BRAUEGG ARZNEIMITTEL KG BERND
Priority to DE19782811695 priority Critical patent/DE2811695A1/en
Publication of DE2811695A1 publication Critical patent/DE2811695A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals

Abstract

New intramuscular medicaments consist of (a) 108 mg. pig brain hydrolysate, (b) 7.5 mg. adenosine phosphate, (c) 7.5 mg. adenosin-phosphoric acid, (d) 7.5 mg. adenosine triphosphoric acid, and (e) 60 mg. rutin. Used to treat arteriosclerosis, lupus erythematodes, parkinsonism and psoriasis. The pig brain hydrolysate is protein-free, i.e. hydrolysis is to the free amino acid level. The therapeutic effect of the prepn. is attributed to supply of substances absent from the body of the patient, thus compensating for genetically-induced metabolic disorders. The adenosine phosphate components of the new medicaments are sufficient to stimulate adenylate cyclase activity. The pig brain hydrolysate provided the amino acid building blocks for the formation of enzymes.

Description

satentals,uruchsatentals, uruch

Oberbegriff: Intramuskulär verabreichbares Arzneimittel zur Behandlung der Arteriosklerose, Lupus eryttematodes, Parkinson und Psoriasis, dadurch gekennzeichnet, daß es aus a) 108 mg Hydrolysat aus Schweinehirn, und zwar gespalten bis zu den Aminosäuren, eiweißfrei in gysiologischer Abstimmung zueinander, b) 7,5 mg Adenosinphosphat c) 7,5 mg Adenosinphosphorsäure d) 7,5 mg Adenosintriphosphorsäure e) 60 mg Rutin besteht.Generic term: drug for treatment that can be administered intramuscularly of atherosclerosis, lupus eryttematodes, Parkinson's and psoriasis, characterized in that it consists of a) 108 mg hydrolyzate from pig brain, namely split up to the Amino acids, protein-free in physiological coordination with one another, b) 7.5 mg adenosine phosphate c) 7.5 mg adenosine phosphoric acid d) 7.5 mg adenosine triphosphoric acid e) 60 mg rutin consists.

Kennzeichnender Teil: Die Erfindung betrifft ein intramuskulär verabreichbares Arzneimittel, das dadurch gekennzeicbnet ist, daß es aus a) 108 mg Hydrolysat aus Sdweinehirn, und zwar gespalten bis zu den Aminosäuren, eiweißfrei in jysiologischer Abstimmung zueinander, b) 7,5 mg Adenosinphosphat c) 7,5 mg Adenosinphosphorsäure d) 7,5 mg Adenosintriphosrfnrsäure e) 60 mg Rutin besteht.Characteristic part: The invention relates to an intramuscularly administrable one Medicinal product which is characterized in that it consists of a) 108 mg hydrolyzate Sdweinebirn, split down to the amino acids, protein-free in physiological Matching each other, b) 7.5 mg adenosine phosphate c) 7.5 mg adenosine phosphoric acid d) 7.5 mg adenosine triphosphoric acid e) 60 mg rutin.

Die wertvollen therapeutischen Effekte werden begründet mit der Wirksamkeit der beschriebenen Injektionslösung des Kombinationspräparates, das dem Körper der Patienten fehlende Substanzen zuführt und ihm dadurch ermöglicht, die genetisch bedingten Stoffwechsel störungen zu kompensieren. The valuable therapeutic effects are justified with the effectiveness the described injection solution of the combination preparation, which the body of the The patient supplies missing substances and thereby enables him to genetically to compensate for metabolic disorders.

Erreicht wird dieser wertvolle therapeutische Effekt durch die gleichzeitige und wechselseitige Stärkung des Zellstoffwechsels und des Stoffwechsels im Zentralnervensystem. This valuable therapeutic effect is achieved through the simultaneous and mutual strengthening of cell metabolism and metabolism in the central nervous system.

Beschreibung Zweck: Neue Injektionslösung zur Verwendung als Arzneimittel mit wertvollen therapeutischen Effekten.Description Purpose: New solution for injection for use as a medicine with valuable therapeutic effects.

Zusammensetzung: 108 mg Hydrolysat aus Schweinehirn, und zwar gespalten bis zu den Aminosäuren, eiweiI3frei in physiologischer Abstimmung zueinander 7,5 mg Adenosinphosphat 7,5 mg Adenosinphosphorsäure 7,5 mg Adenosintriphosphorsäure 60 mg Rutin Vorteile: Durch die neue Injektionslösung ist es möglich, daß die Therapie der genannten Indikationen ambulant gehandhabt werden kann. Die Adenosinphosphatbestandteile genügen, um die Adenylatzyklase-Aktivität anzuregen. Durch die Aminosäurenbeigaben wird leicht zugängliches Füllmaterial zur Bildung von Enzymen geliefert und so die Kompensation von genetisch bedingten Stoffwechsel störungen ermöglicht.Composition: 108 mg hydrolyzate from pig brain, split down to the amino acids, protein-free in physiological coordination with one another 7.5 adenosine phosphate 7.5 mg adenosine phosphoric acid 7.5 mg adenosine triphosphoric acid 60 mg rutin Advantages: With the new injection solution it is possible that the therapy of the indicated indications can be handled on an outpatient basis. The adenosine phosphate components suffice to stimulate adenylate cyclase activity. By adding amino acids easily accessible filling material is supplied for the formation of enzymes and so the Compensation for genetically caused metabolic disorders.

Claims (1)

Patentans prucH Ein weiterer Patentanspruch ist dadurch gegeben, daß bis heute z.b. die Psoriasis (Schuppenflechte) nur örtlich-symptomatisch behandelt werden konnte.Patent claim A further patent claim is given in that until today e.g. psoriasis (psoriasis) is only treated locally and symptomatically could be. Die neue Wirkstoffkombination ist ein bedeutender Schritt in Richtung Kausaltherapie, wobei erstmalig die genetisch bedingte Stoffwechsel störung kompensiert werden kann.The new combination of active ingredients is an important step in this direction Causal therapy, which for the first time compensates for the genetic metabolic disorder can be. Die deutliche cerebrale Mehrleistung durch das Hirnhydrolysat (Aminosäurenmuster des Gehirns) in Verbindung mit der Verhinderung der Fragilität der Kapillaren durch den starken Anteil von Rutin sowie durch den substituierenden Einfluß der Adenosinphosphatkom,bination auf energetische Prozesse im Organismus, wird eine bis dato nich bekannte erfolgreiche Therapie der Arteriosklerose ermöglicht.The clear cerebral performance through the brain hydrolyzate (amino acid pattern of the brain) in connection with the prevention of capillary fragility the high proportion of rutin and the substituting influence of the adenosine phosphate combination on energetic processes in the organism, will be a hitherto unknown success Therapy of atherosclerosis enables. Die regenwative Leistung dieser Wirkstoffkombination deutet zusätzlich auf eine wesentliche Bereicherung des Arzneimittelschatzes in der Gerontologie hin.The regenerative performance of this combination of active ingredients is an additional indication towards a substantial enrichment of the drug treasure in gerontology.
DE19782811695 1978-03-17 1978-03-17 Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis Withdrawn DE2811695A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19782811695 DE2811695A1 (en) 1978-03-17 1978-03-17 Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782811695 DE2811695A1 (en) 1978-03-17 1978-03-17 Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis

Publications (1)

Publication Number Publication Date
DE2811695A1 true DE2811695A1 (en) 1979-09-27

Family

ID=6034744

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19782811695 Withdrawn DE2811695A1 (en) 1978-03-17 1978-03-17 Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis

Country Status (1)

Country Link
DE (1) DE2811695A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650433A (en) * 1993-07-09 1997-07-22 Kureha Chemical Industry Co., Ltd. Chondroprotective agents
CN113908174A (en) * 2021-10-29 2022-01-11 北京四环制药有限公司 Efficient and safe preparation method and application of cerebroprotein hydrolysate
CN114699418A (en) * 2022-04-02 2022-07-05 遵义医科大学 Application of rutin in treating psoriasis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
1981, Heft 5, S. 394-403 *
DE-Z.: Erfahrungheilkunde 1979, Heft 11, S. 874-876 *
DE-Ztschr. für Hauterkrankungen 52, (8) 466-469 (1977) *
Rote Liste 1976, Editio Cantor, Aulendorf, 47007b Rutinion 70194C2 Cerebrolysin 36022B Triadenyl 54097B Actihaemyl 36116Cb Actovegin *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650433A (en) * 1993-07-09 1997-07-22 Kureha Chemical Industry Co., Ltd. Chondroprotective agents
CN113908174A (en) * 2021-10-29 2022-01-11 北京四环制药有限公司 Efficient and safe preparation method and application of cerebroprotein hydrolysate
CN114699418A (en) * 2022-04-02 2022-07-05 遵义医科大学 Application of rutin in treating psoriasis

Similar Documents

Publication Publication Date Title
US6776984B1 (en) Induced regeneration and repair of damaged neurons and nerve axon myelin
Fouts et al. Treatment of human pellagra with nicotinic acid
Schumacher et al. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids
DE69815230T2 (en) Use of transduced myogenic cells for pain relief and for the treatment of behavioral and cognitive abnormalities
Falchetto et al. The action of carnitines on cortical neurons
EP0188810B1 (en) Use of dipeptide derivatives for the prevention or treatment of post-traumatic spinal and/or cerebral nerve disorders
US4816439A (en) The use of human growth hormone for the treatment of intoxicated individuals
EP0185210A2 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
Desiraju et al. Activity of single neurons in the hypothalamic feeding centers: Effect of 2-deoxy-d-glucose
DE3510654A1 (en) NEW PHARMACEUTICAL APPLICATION OF CGRPS
DE2811695A1 (en) Cpds. contg. pig brain hydrolysate and adenosine phosphate derivs. - medicaments for intramuscular treatment of arteriosclerosis, lupus parkinsonism and psoriasis
DE19544768C1 (en) Use of a combination of pentoxifylline with type I interferons to treat multiple sclerosis
US4621074A (en) Method of treating smoking withdrawal syndrome
JPH0228580B2 (en)
DE4343034C1 (en) Use of pentoxifylline for the treatment of multiple sclerosis
DE2357074A1 (en) VASCULAR-WIDENING AND SYMPATHOLYTIC MEDICINAL PRODUCT
EP0144489B1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
DE4217396A1 (en) Metrifonate-containing drug
Stephens et al. Retrograde degeneration of basal forebrain cholinergic neurons after neurotoxin lesions of the neocortex: application of ganglioside GM1
Jensen Vasopressin therapy in Parkinson's disease
JP3167714B2 (en) Nerve cell protective agent
DE4004549A1 (en) Use of glutamic acid or derivs. for treating hypertension - by oral admin., effective for patients not responding to other treatments
DE1939008A1 (en) Curing disturbances in brain functioning - caused by defective blood circulation
DE3633651A1 (en) Use of fractions of thymus and spleen extracts for the treatment of psoriasis
DeFelice et al. Gangliosides—Clinical overview

Legal Events

Date Code Title Description
OF Willingness to grant licences before publication of examined application
8127 New person/name/address of the applicant

Owner name: BRAUEGG ARZNEIMITTEL KG BERND SOTEK, 7570 BADEN-BA

8110 Request for examination paragraph 44
8139 Disposal/non-payment of the annual fee